Unlock instant, AI-driven research and patent intelligence for your innovation.
Glycyrrhizin-containing suppository compositions for rectal infusion
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A glycyrrhizic, rectal technique
Inactive Publication Date: 2007-06-13
MINOPHAGEN PHARMA
View PDF4 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0017] However, these oral preparations must add medium-chain fatty acids such as capric acid, which is highly irritating to the mucous membranes, as an absorption enhancer, and there are safety problems as mentioned above.
Also, as mentioned above, almost all of GL is decomposed into GA in the digestive tract, so its effect is not sufficient
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1～6 and comparative example 1
[0137] Mix monoammonium glycyrrhizinate and oily base agent according to the mixing amount (mass %) shown in Table 1, further add nonionic surfactant, stir evenly in a mortar, add water, carry out thorough mixing, and obtain the rectal injection containing GL Suppository compositions.
[0138] In addition, the abbreviations in Table 1 have the following meanings.
[0139] GL-NH 4 : Monoammonium glycyrrhizinate
[0140] J-1811: Sucrosefatty acid ester with HLB of 11 (manufactured by Mitsubishi Chemical Fu-zu Co., Ltd.)
[0141] S-24D: Polyglycerol fatty acid ester with HLB of 10 (manufactured by Mitsubishi Chemical Fu-zu Co., Ltd.)
[0142] L-7D: Polyglycerol fatty acid ester with HLB of 17 (manufactured by Mitsubishi Chemical Fu-zu Co., Ltd.)
[0143] PGMSV: Polyglycerol fatty acid ester with HLB of 14 (manufactured by Nisshin Oirio Co., Ltd.)
[0228] According to the composition and mixing amount (mass %) shown in Table 9~11, utilize homogenizer, evenly suspend monoammonium glycyrrhizinate (GL-NH 4 ), an oily base, a nonionic surfactant, purified water or an aqueous alkali solution, and fully stirred to prepare a rectal injection suppository composition containing GL. In addition, in Example 25, gerline (Benzalkonium salt) was further added to prepare a composition.
[0229] In Examples 19 to 27 using the above-mentioned aqueous alkali solution, the ratio (mass %) of the water component and the alkali component in the composition is shown in parentheses.
[0230] In addition, the abbreviations in Tables 9 to 11 have the following meanings.
[0231] SS: Sucrosefatty acid ester with HLB of 19 (manufactured by Daiichi Kogyo Pharmaceutical Co., Ltd.)
[0232] F-160: Sucrosefatty acid ester with HLB of 15 (manufactured by Daiichi Kogyo Pharmaceutical Co., Ltd.)
[0233] J-1811: HLB is 11 sucrose fatty acid ester (ma...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Property
Measurement
Unit
weight
aaaaa
aaaaa
Login to View More
Abstract
A glycyrrhizin-containing suppository composition for rectal infusion which comprises at least one member selected from among glycyrrhizin and pharmaceutically acceptable salts thereof, a nonionic surfactant, an oily base, and water and which exhibits a solid-liquid phasetransition point of 10 to 4500Pa at 37 DEG C; and a glycyrrhizin-containing suppository composition for rectal infusion which comprises at least one member selected from among glycyrrhizin and pharmaceutically acceptable salts thereof, an oily base, water, and an alkali.
Description
technical field [0001] The present invention relates to rectal injection suppository composition containing glycyrrhizic acid and its preparation method, medicine for liver disease, medicine for skindisease, medicine for antiallergic reaction, medicine for treating SARS and medicine for treating AIDS containing the composition for rectal injection suppository containing glycyrrhizic acid . [0002] This application claims priority based on Japanese application No. 2004-191275 filed on June 29, 2004 and Japanese application No. 2004-371222 filed on December 22, 2004, and the contents of the earlier applications are cited in this application. Background technique [0003] Glycyrrhizic acid (hereinafter referred to as GL) and its salts have been known to have a wide range of physiological activities such as anti-allergic effects, anti-inflammatory effects, immune regulation, liver cell damage inhibition, liver cell proliferation promotion, and virusreproduction inhibition. h...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More